Preclinical pharmacology modeling of chimeric antigen receptor T therapies.

Abstract

Chimeric antigen receptor (CAR) T cells have largely been successful in treating hematological malignancies in the clinic but have not been as effective in treating solid tumors, in part, owing to poor access and the immunosuppressive tumor microenvironment. In addition, CAR-T therapy can cause potentially life-threatening side effects, including cytokine release syndrome and neurotoxicity. Current preclinical testing of CAR-T therapy efficacy is typically performed in mouse tumor models, which often fails to predict toxicity. Recent developments in humanized models and transgenic mice as well as in vitro three-dimensional organoids in early development and nonhuman primate models are being adopted for CAR-T cell efficacy and toxicity assessment. However, because no single model perfectly recapitulates the human immune system and tumor microenvironment, careful model selection based on their respective pros and cons is crucial for adequate evaluation of different CAR-T treatments, so that their clinical development can be better supported.

• Authors: Rajendra Kumari, Xuesong Ouyang, Jingjing Wang, Xiaoxi Xu, Meiling Zheng, Xiaoyu An, Qi-Xiang Li
• Journal: Current opinion in pharmacology (Curr Opin Pharmacol) Vol. 61 Pg. 49-61 (12 2021) ISSN: 1471-4973 [Electronic] England
• PMID: 34619442 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021. Published by Elsevier Ltd.

Chemical References

• Receptors, Antigen, T-Cell
• Receptors, Chimeric Antigen

Topics

• Animals
• Immunotherapy, Adoptive
• Mice
• Neoplasms (drug therapy)
• Receptors, Antigen, T-Cell (genetics)
• Receptors, Chimeric Antigen
• T-Lymphocytes
• Tumor Microenvironment